Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Capital Reduction

24 Aug 2016 17:16

RNS Number : 0706I
Premier Veterinary Group PLC
24 August 2016
 

PREMIER VETERINARY GROUP PLC

("PVG" or the "Company")

Capital Reduction

 

 

Premier Veterinary Group plc announces that, further to a resolution passed by Shareholders at the Annual General Meeting held on 23 March 2016, in order to facilitate the proposed reduction of PVG's share capital (the "Capital Reduction"), full details of which were set out in the Notice of Annual General Meeting dated 28 January 2016 (the "Notice"), the Company has today issued and allotted 1,690,315 deferred shares of 90 pence each (the "Deferred Shares") to Sue Steven, the Secretary of the Company.

The deferred shares do not entitle holders to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend or other distribution or to participate in any return on capital on a winding up other than the nominal amount paid on such shares following a substantial distribution to the holders of ordinary shares in the Company. Accordingly, the deferred shares are, for all practical purposes, valueless.

As set out in the Notice, the share capital of the Company will be reduced by cancelling and extinguishing both the Deferred Shares together with all other deferred shares of 90 pence each in the capital of the Company on 30 August 2016.

The Company is in the process of making an application to the High Court of Justice, Chancery Division, for approval for the reduction of PVG's share capital and cancellation of the entire amount standing to the credit of the Company's share premium account.

A further announcement will be issued in due course.

 

For further information, please contact:

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Daniel Smith, Chief Financial Officer

 

Zeus Capital Limited Tel: +44 (0)203 829 5000

Giles Balleny, Director, Corporate Finance

Hugh Kingsmill Moore, Director, Sales 

 

Square1 Consulting Tel: +44 (0)207 929 5599

David Bick/Brian Alexander

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CARQZLFLQVFFBBF
Date   Source Headline
14th Apr 20102:09 pmRNSRule 8.3- Ark Therapeutics Group PLC
14th Apr 201011:41 amRNSEPT Disclosure-Amendment
13th Apr 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
13th Apr 201011:34 amRNSEPT Disclosure
13th Apr 201011:31 amRNSRule 8.3- ARK THERAPEUTICS
13th Apr 201011:29 amRNSEPT Disclosure
12th Apr 201011:22 amRNSEPT Disclosure
12th Apr 201010:19 amRNSEPT Disclosure
12th Apr 20107:00 amRNSResearch Update
9th Apr 201011:35 amRNSEPT Disclosure
9th Apr 201011:33 amRNSEPT Disclosure- Amendment
9th Apr 20109:28 amRNSEPT Disclosure
8th Apr 20102:43 pmRNSEPT Disclosure-Amendment
8th Apr 201012:27 pmRNSEPT Disclosure
8th Apr 201010:43 amRNSRule 8.3- ARK THERAPEUTICS
8th Apr 20108:33 amRNSEPT Disclosure
7th Apr 20104:08 pmRNSAnnual Information Update
7th Apr 201010:59 amRNSRule 8.3- ARK THERAPEUTICS
1st Apr 201011:03 amRNSArk Therapeutics Group plc
1st Apr 201011:00 amRNSEPT Disclosure
1st Apr 201010:37 amRNSEPT Disclosure
31st Mar 20103:42 pmRNSTotal Voting Rights
31st Mar 20102:00 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
31st Mar 201010:37 amRNSEPT Disclosure
30th Mar 201012:48 pmRNSEPT Disclosure
30th Mar 201012:42 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201010:53 amRNSEPT Disclosure
24th Mar 201011:52 amRNSEPT Disclosure
24th Mar 201011:15 amRNSEPT Disclosure
24th Mar 201010:25 amBUSRule 8.3 - Ark Therapeutics Group plc
22nd Mar 20101:48 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:42 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:24 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
22nd Mar 201011:45 amRNSEPT Disclosure
22nd Mar 201010:18 amRNSEPT Disclosure
19th Mar 20104:58 pmRNSRule 8.3- (Ark Therapeutics Group Plc)
19th Mar 20102:56 pmRNSRule 8.3- Ark Therapeutics Group plc
19th Mar 20101:30 pmBUSRule 8.3 - Ark Therapeutics Group plc
19th Mar 201011:45 amRNSEPT Disclosure
19th Mar 201010:30 amRNSEPT Disclosure
18th Mar 201012:14 pmRNSEPT Disclosure
17th Mar 201010:38 amRNSEPT Disclosure
16th Mar 20103:55 pmRNSHolding(s) in Company
16th Mar 201011:12 amRNSEPT Disclosure
15th Mar 201011:30 amRNSEPT Disclosure
15th Mar 201010:34 amRNSEPT Disclosure
11th Mar 201011:49 amRNSEPT Disclosure
10th Mar 20104:40 pmRNSSecond Price Monitoring Extn
10th Mar 20104:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.